Skip to content

Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries

Added Value, Performance and Acceptance of the GFAP-UCH-L1 Pair in the Evaluation of Subjects with Mild Traumatic Brain Injury (MTBI) At Intermediate Risk of Complications

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05885529
Acronym
GUEST
Enrollment
1500
Registered
2023-06-02
Start date
2024-04-19
Completion date
2026-03-30
Last updated
2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

UCHL1, GFAP, CT scan

Brief summary

The goal of this observational study is to evaluate the performance of UCH-L1 and GFAP combined in patients with a mild traumatic brain injury. The main question : • Does the combination of UCH-L1 and GFAP can exclude brain injuries detected with CT scan in the first twelve hours after a mild traumatic brain injury? Participants will do the exams planed in routine care and : * during the expected blood sampling an additional blood sample will be done, * seven days after the discharge a call will be done by the investigator.

Detailed description

Main study The main study includes subjects presenting to the emergency department within 12 hours of mild traumatic brain injury with an intermediate risk of clinical worsening or intracranial lesions. The participants have at least one of the following characteristics, as defined in the French recommendations * \> 65 years treated with anti-platelet agents * Glasgow Score \< 15 at two hours after the trauma if associated intoxication (alcohol, narcotic, psychotropic) * Trauma with high kinetics (for information only: a risk mechanism (pedestrian knocked down by a motorized vehicle, ejection from a vehicle, fall from more than 3 steps (more than one meter), etc.), * Amnesia of facts \> 30 min before the trauma The study includes clinical sites in France and Monaco. Participants have a blood sample and a brain scan as part of the care. The participation of subjects in the study will not influence their treatment. Ancillary study The ancillary study uses qualitative research methodology to assess acceptance by physicians and patients of a biological test rather than a CT scan to exclude intracranial complication after mild traumatic brain injury. The study will takes place in the emergency department of the Nice University Hospital Center (CHU of Nice). It will include 30 subjects: 15 subjects presenting to the emergency room for mild traumatic brain injury and included in the main protocol and 15 prescribing emergency physicians. The participation of subjects in the study will not influence their treatment.

Interventions

OTHERUCH-L1 GFAP

measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury

Sponsors

BioMérieux
CollaboratorINDUSTRY
Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
University Hospital, Clermont-Ferrand
CollaboratorOTHER
Hospices Civils de Lyon
CollaboratorOTHER
Poitiers University Hospital
CollaboratorOTHER
University Hospital, Angers
CollaboratorOTHER_GOV
Centre Hospitalier Universitaire de Nīmes
CollaboratorOTHER
Centre Hospitalier Universitaire de Nice
CollaboratorOTHER
Nantes University Hospital
CollaboratorOTHER
University Hospital, Montpellier
CollaboratorOTHER
Centre Hospitalier Universitaire Dijon
CollaboratorOTHER
University Hospital, Grenoble
CollaboratorOTHER
Fondation Hôpital Saint-Joseph
CollaboratorOTHER
CHU de Tours
CollaboratorUNKNOWN
Centre Hospitalier Princesse Grace
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Traumatic brain injury defined by * Impact on the skull or the face AND OR * Acceleration / deceleration * Glasgow Coma Scal 13, 14 or 15 * One of the following 4 criteria: * \> 65 years treated with anti-platelet agent, * GCS \< 15 two hours after the trauma if associated intoxication (alcohol, narcotic, psychotropic), * Trauma with high kinetics (for information only: a risk mechanism (pedestrian knocked down by a motorized vehicle, ejection from a vehicle, fall from more than 3 steps (more than one meter), etc.), * Amnesia of facts \> 30 min before the trauma. * Having a blood sample taken as part of care with a delay between the clinical event and the biological sample \< 12 hours * Having a CT-scan prescription as part of the MTBI evaluation * Patient who signed an informed consent form

Exclusion criteria

* Person not affiliated or not benefiting from a health insurance scheme. * Person under judicial protection. * Person with restrictions of freedom or subject to Articles L.3212-1 and L.3213-1, and not included in Article L.1122-8 of the French CSP * Blood collection time \> 12 hours * Subjects for which a scan would be carried out systematically, including: * GCS \<13 (moderate or severe trauma), * congenital hemostasis disorders or patient on anti-coagulant treatment, * clinical signs evoking a fracture of the vault or the base of the skull, * more than one episode of vomiting, * post-traumatic convulsion, * focal neurological deficit. * Obstacle to follow-up at D7 * Malignant melanomas

Design outcomes

Primary

MeasureTime frameDescription
performance of UCH-L1 and GFAP combined to rule out intracranial complication after MTBIduring the first 12 hoursPercentage of intracranial lesion excluded by UCH-L1 and GFAP combined, versus the CT scan, within the first 12 hours following a MTBI

Secondary

MeasureTime frameDescription
Performance of UCH-L1 and GFAP combined to rule out intracranial bleeding after MTBIduring the first 12 hoursPercentage of intracranial bleeding excluded by UCH-L1 and GFAP alone or combined, versus the CT scan, within the first 12 hours following a MTBI
Comparation of UCH-L1 and GFAP combined or alone, to S100b protein (PS100b)during the first 12 hours with a focus every 3 hoursPercentage of intracranial complication identified by UCH-L1 and GFAP, alone or in combination, versus PS100b within the first 12 hours following a MTBI .
Predicted impact of using UCH-L1 and GFAP combinedday 7Variation of resource consumption by the use of UCH-L1 and GFAP
Performance of UCHL-1 and GFAP alone or combined to predict complicationsduring the first 7 daysPercentage of complications avoided by the use of UCH-L1 and GFAP, alone or combined.

Other

MeasureTime frameDescription
ancillary outcomeDay 1Acceptability by a semi-directed interview of a new strategy integrating the use of biomarkers for the management of MTBI by patients and investigators

Countries

France, Monaco

Contacts

Primary ContactYann-Erick CLAESSENS, MD-PhD
yann-erick.claessens@chpg.mc97 98 99 00
Backup ContactNicolas RIJO, CRA
recherche.clinique@chpg.mc97 98 99 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026